



CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS

Cerebral Venous Thrombosis

Seventh Edition, 2024

**Appendix One & Two: Writing Group Members and External
Reviewers**

*Field T.S, Mandzia J (Writing Group Chairs)
on Behalf of the Canadian Stroke Best Practice Recommendations
Cerebral Venous Thrombosis Writing Group and in collaboration with the
Canadian Stroke Consortium*

© 2024 Heart and Stroke Foundation of Canada

APPENDIX ONE: CEREBRAL VENOUS THROMBOSIS SCIENTIFIC WRITING GROUP AND AUTHORS 2024

NAME	PROFESSIONAL ROLE	LOCATION	DECLARED CONFLICTS OF INTEREST
Thalia S. Field, MD, MHSc, FRCPC Co-Chair	Associate Professor, Sauder Family/Heart and Stroke Professor of Stroke Research, Division of Neurology, University of British Columbia, Stroke Neurologist, Vancouver Stroke Program	Vancouver, British Columbia	Sauder Family/Heart and Stroke Professorship of Stroke Research, UBC for Protected time; Professional Investigator Awards from Bayer Canada, Heart and Stroke Foundation, CIHR, Health Research BC (Michael Smith); In-kind study medication (Bayer) for CIHR Project; research grants from the Heart and Stroke Foundation of Canada and Health Research BC; Educational events, personal fees from HLS Therapeutics; Expert witness - personal fees from AstraZeneca, Bayer Canada, Roche, HLS Therapeutics; Board member, DESTINE Canada and DESTINE Canada Stock options.
Jennifer Mandzia, MD, PhD, FRCPC Co-Chair	Associate Professor, Department of Clinical Neurological Sciences, Western University, Medical Director Southwestern Ontario Stroke Network and LHSC Stroke Program	London, Ontario	Received Study specific payments for participating site in the SECRET study; Member of the SECRET Study Steering Committee.
Derek B. Debicki, MD, PhD FRCPC, CSCN (EEG)	Assistant Professor, Neurocritical Care & Epilepsy, Department of Clinical Neurological Sciences, Western University, London Health Sciences Centre	London, Ontario	Member of speakers' bureau for UCB Canada.
Jonathan Gorman MD, FRCPC	Clinical Assistant Professor, Division of Neurology, University of British Columbia; Stroke Neurologist, Vancouver Stroke Program	Vancouver, British Columbia	Received honoraria from Astra Zeneca; Principal Investigator for the OCEANIC-Stroke study with Bayer; support for attending investigator meetings from Bayer.
Manraj (Raju) K.S. Heran, MD, FRCPC	Associate Professor, Division of Neuroradiology, Department of Radiology, University of British Columbia and Vancouver General Hospital; Section of Pediatric Interventional	Vancouver, British Columbia	None to declare

NAME	PROFESSIONAL ROLE	LOCATION	DECLARED CONFLICTS OF INTEREST
	Radiology, BC Children's Hospital.		
Leonard A. Levin, MD, PhD, FCAHS	Distinguished James McGill Professor and Chair of Ophthalmology and Visual Sciences, McGill University	Montreal, Quebec	Received grant finding from CIHR, US Department of Defense, NIH, Canada Research Chairs, Canadian Foundation for Innovation; Royalties from Elsevier for books unrelated to manuscript; Consulting fees from Dompe, Perfuse, Quark, Santen, Neuroptika, Annexon, Roche, Galimedix, Eyeevensys, UNITY, Janssen, LifeBiosciences, Prilenia. Honoraria at various non-profit universities and scientific conferences unrelated to manuscript; Advisory board member for Gilbert Family Foundation and National Eye Institute; Former chair of Ophthalmology and Visual Sciences at McGill.
Mahendra Moharir MD	Professor, Dept. of Pediatrics, Temerty Faculty of Medicine, University of Toronto; Clinical Director, Children's Stroke Program, Division of Neurology, The Hospital for Sick Children	Toronto, Ontario	None to declare
Lissa Peeling, MD, FRCSC	Associate Professor, Department of Surgery, Division of Neurosurgery, University of Saskatchewan	Saskatoon, Saskatchewan	Serves as DSMB/CEC member for 2 trials with Styker Neurovascular.
Kanjana S Perera MD, FRCPC	Associate Professor Medicine (Neurology), McMaster University	Hamilton, Ontario	Received an education grant from Bayer AG; Clinical trial investigator for NAVIGATE-ESUS, Y-ESUS, CATIS-ICAD, AXIOMATIC, SECRET, TIMELESS, ACT.
Deborah Siegal, MD, MSc, FRCPC	Associate Professor and Scientist, Ottawa Hospital Research Institute, University of Ottawa Hematologist, Department of Medicine, The Ottawa Hospital	Ottawa, Ontario	Received consulting fees from Astra Zeneca (paid indirectly to institution); honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Astra Zeneca, BMS-Pfizer, Roche, Servier; board member for Thrombosis Canada, Anticoagulation Forum, Hemostasis and Thrombosis Research Society.

NAME	PROFESSIONAL ROLE	LOCATION	DECLARED CONFLICTS OF INTEREST
Steve Verreault, MD, FRCPC	Clinical professor Université Laval, Department of Medecine (Neurology); Stroke Neurologist, Head of Neurology, Hôpital Enfant- Jésus, CHU de Québec .	Quebec City, Quebec	None to declare
Wein, Theodore MD, FRCPC, FAHA	Assistant Professor of Neurology and Neurosurgery, McGill University		Holds grants from CIHR, Ipsen, AbbVie; receives consulting fees from AbbVie, Servier, Ipsen; honoraria for lectures from Ipsen, Servier, AbbVie; support for attending meetings from Ipsen; advisory board member for Pacers, Sunrise, Revance.
Smith, Eric E. MD, MPH, FRCPC, FAHA	Professor of Neurology, Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary; Neurologist, Calgary Stroke Program, Foothills Medical Centre	Calgary, Alberta	Nothing to declare
Mountain, Anita MD, FRCPC	Assistant Professor Division of Physical Medicine & Rehabilitation, Department of Medicine, Dalhousie University; Medical Lead, Acquired Brain Injury Program, Queen Elizabeth II Health Sciences Centre.	Halifax, Nova Scotia	Received grants from CIHR, Brain Canada, Heart and Stroke Foundation, Canadian Partnership for Stroke Recovery Governors of the University of Calgary Drs. Miriam and Adelson Medical Research Foundationship for Stroke Recovery; Site QI for Multi-centre studies FLOW: FLuoxetine to Open the critical time period Window to improve motor recovery after stroke, CAMAROS: The CANadian Maraviroc Randomized controlled trial to Augment Rehabilitation Outcomes after Stroke, MODEX: MODafinil and EXercise for PostStroke Fatigue; Rehab Co-Lead for Canadian Stroke Best Practice Advisory Committee, Heart and Stroke (no remuneration).

APPENDIX TWO: CEREBRAL VENOUS THROMBOSIS EXTERNAL REVIEWERS 2024

NAME	PROFESSIONAL ROLE	LOCATION	DECLARED CONFLICTS OF INTEREST
Diana Aguiar de Sousa, MD, PhD	Assistant Professor, University of Lisbon, Faculdade de Medicina, Universidade de Lisboa; Consultant Neurologist, Lisbon Central University Hospital and Faculty of Medicine.	Lisbon, Portugal	Investigator or national coordinator: (ELAN) for DISTAL trial, LIBREXIA STROKE, ELAN trial, BIA-2093- 213. Received personal fees for AstraZeneca and Organon advisory board participation, travel support from Boehringer Ingelheim, DSMB participation for the SECRET trial (University of British Columbia) and speaking fees from Bayer and Bial. Speaker bureau for Bayer and Bial
Lana A. Castellucci, MD, MSc	Associate Professor, University of Ottawa, Department of Medicine; Scientist, Ottawa Hospital Research Institute.	Ottawa, Ontario	National New Investigator Award from the Heart and Stroke Foundation of Canada. Grant or honorarium: LEO Pharma
Luciana Catanese, MD	Associate Professor of Medicine, Division of Neurology, McMaster University; Director, Hamilton General Hospital Stroke Unit and McMaster Stroke Fellowship Program.	Hamilton, Ontario	Speaker and consultant fees from ROCHE and Servier Inc.
Johnathon Coutinho, MD, PhD	Associate Professor, Amsterdam University Medical Centers, University of Amsterdam; Stroke Neurologist.	Amsterdam, Netherlands	Co-founder and shareholder for Trianect BV. Received grant support from Boehringer Ingelheim, Bayer, Astra Zeneca
Laura Gioia, MD, MSc	Stroke Neurologist Clinical Assistant Professor, Neurosciences, Centre Hospitalier de l'Université de Montréal	Montréal, Quebec	Advisory Board Honoraria/Speaker fees: AstraZeneca, Bayer, BMS Pfizer. Grant in Aid from Heart and Stroke Foundation of Canada. Currently participating, or have participated within the past two years, in a clinical trial: ENRICH-AF, COVASC-ich, FASTEST (Site Principal Investigator)
Brett Graham, MD, FRCPC	Assistant Professor, University of Saskatchewan; Medical Director, Stroke Prevention Clinic, Royal University Hospital.	Saskatoon, SK	Member of Saskatchewan chapter of the Heart and Stroke Foundation of Canada. Received grant or honorarium from HLS Therapeutics, member of a National Stroke Neurologist Expert Panel for icosapent ethyl. Local PI for Study of Rivaroxaban for CeREbral Venous Thrombosis (SECRET)

NAME	PROFESSIONAL ROLE	LOCATION	DECLARED CONFLICTS OF INTEREST
Sherry Hu, MD, FRCPC, FCSC	Assistant Professor, Dalhousie University	Halifax, Nova Scotia	Site PI for OCEANICS. Sub-I for ENRICH AF, ESCAPE MEVO, ESCAPE NEXT, ACT, ANNEXA, and TEMPO-2. Received \$200 honorarium for writing a stroke book chapter for Canadian Pharmacists Association.
Sylvain Lanthier, MD OD, CSPQ	Associate professor, University of Montreal, Faculty of Medicine, Department of Neurosciences; Stroke Neurologist, Hôpital du Sacré-Coeur de Montréal.	Montreal, Quebec	Steering Committee for Bayer, Brain AF. Speaker for BMS-Pfizer, Servier. Grant or honorarium from BMS-Pfizer, Servier, Ad Board member.
Neshika Samarasekera, PhD, MRCP	Honorary Clinical Senior Lecturer, University of Edinburgh; Consultant Neurologist.	Edinburgh, Scotland	Grant or honorarium from UK Stroke Association.
Arturo J. Tamayo, MD, FAHA, MSc, FAAN	Assistant Professor of Neurology, University of Manitoba; Consultant, HSC Winnipeg Stroke Clinic; Director, Brandon Stroke Prevention Clinic.	Winnipeg, Manitoba	Principal Investigator from ARCADIA and ENRICH AF.
Katie White, B.Sc.PT, M.Sc.	Director, Health Systems, Heart and Stroke Foundation of Canada; Previously, Lead, Provincial Clinical Initiatives and Innovation, Stroke Services BC.	Port Moody, British Columbia	Nothing to declare